Checkmate Pharmaceuticals Announces Appointment of Keith T. Flaherty, M.D. to its Board of Directors
Business Wire 9-Apr-2019 7:00 AM
Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical
company focused upon activation of innate immunity to treat advanced
cancer, today announced the addition of Keith T. Flaherty, M.D. to its
Board of Directors.
Dr. Flaherty is a Professor of Medicine at Harvard Medical School,
Associate Physician of Medicine, Hematology/Oncology at Massachusetts
General Hospital, Director of Clinical Research, Massachusetts General
Hospital Cancer Center, and Editor-in-Chief of Clinical Cancer
Research. He co-founded and served on the Board of Directors of Loxo
Oncology, Inc. until its acquisition by Eli Lilly and Company, and he
currently serves on the Board of Directors of Clovis Oncology, Inc.
(NASDAQ:CLVS). Dr. Flaherty has a Bachelor of Science from Yale
University and a medical degree from Johns Hopkins University. Dr.
Flaherty trained in internal medicine at Brigham and Women's Hospital
and completed a medical oncology fellowship at the University of
Pennsylvania.
"We welcome Dr. Flaherty to our Board of Directors and are looking
forward to his guidance during the exciting times ahead. Keith's
experiences both as a clinical researcher developing innovative oncology
products and as a Board member of development-stage oncology companies
will be tremendously helpful as we continue to advance Checkmate's
mission to provide transformative new treatment options for oncology
patients," commented Barry Labinger, President and CEO of Checkmate
Pharmaceuticals.
"I am excited to join the Checkmate Board at a critical time, as the
company advances toward definitive trials to confirm the benefit of
CMP-001, having established proof-of-concept that the agent can overcome
resistance to PD-1 antibody therapy in melanoma," commented Dr.
Flaherty. "I believe CMP-001 offers promise to enhance immunotherapy for
patients with a variety of types of cancer."
About Checkmate
Checkmate Pharmaceuticals is a clinical stage company that is leveraging
its expertise in the field of CpG oligonucleotides to discover and
develop immunotherapies designed to increase the efficacy of existing
immunotherapies and to provide new treatment options for patients and
their healthcare providers. Checkmate's lead product candidate, CMP-001,
is an investigational cancer immunotherapeutic that has been shown to
reverse resistance to PD-1 therapy in some patients.
Checkmate is a privately held company headquartered in Cambridge, MA.
Information regarding Checkmate is available at www.checkmatepharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190409005355/en/
